Anti-gliadin IgA

If you have been wondering whether your body is mounting an immune reaction to gluten in your gut, this test is one window into that question. It looks for an antibody, called anti-gliadin IgA, that gut immune cells release into the intestine in response to gliadin, the main protein in wheat gluten.

This is a research-grade marker, not an established celiac diagnostic. The strongest available evidence shows it misses most cases of celiac disease in children with symptoms, so it should not be used to confirm or rule out the disease on its own. Treat it as one signal to consider alongside validated celiac testing, not as a verdict.

What This Test Actually Measures

Anti-gliadin IgA is an antibody of the IgA class that binds gliadin, one of the proteins in wheat gluten that the immune system can react to. The stool version measures antibodies released into the gut by immune cells in the intestinal lining, rather than antibodies circulating in the blood. Intestinal lavage studies have shown that gut-secreted antibodies can be detected in the bowel contents, which is what makes a stool-based version of this assay possible.

A high result suggests that your gut immune system is producing antibodies against gliadin and shedding them into the intestinal lumen. A low result suggests little detectable luminal IgA response, but it does not rule out gluten-related disease. People with IgA deficiency, for example, can produce little IgA at all, which is why standard celiac workups always measure total IgA alongside antibody tests.

Why It Falls Short as a Celiac Screen

The cleanest test of stool anti-gliadin IgA for diagnosing celiac disease comes from a validation study of symptomatic children. Using the test maker's cutoffs, the stool antibody assay caught only about 6 out of every 100 children with biopsy-confirmed celiac disease, while correctly clearing 97 out of every 100 children without the disease. In plain terms, a negative stool result missed almost every actual case. The authors concluded the test was not suitable for screening symptomatic children.

In a follow-up analysis from the same validation study, researchers tried to rescue the test by lowering the cutoff and combining it with a second stool assay. The sensitivity rose to 82 out of 100 cases caught, but the specificity dropped to 58 out of 100 non-cases correctly cleared. That means a positive combined result would be wrong nearly half the time. A 2024 review of fecal biomarkers in celiac disease reached a similar verdict: stool antibody markers, including anti-gliadin, have produced inconsistent results and are not yet a reliable substitute for small-bowel biopsy.

How It Compares to Standard Celiac Testing

Mainstream celiac diagnosis does not use stool anti-gliadin IgA. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition recommends measuring total serum IgA together with serum anti-tissue transglutaminase IgA (tTG-IgA, an antibody against an enzyme in your gut lining) as the best first-line strategy. In real-world data from a large United Arab Emirates cohort, serum tTG-IgA caught about 90 out of 100 biopsy-confirmed cases and correctly cleared 84 out of 100 non-cases. Pooled across many studies, serum tTG-IgA performs even better, with a U.S. Preventive Services Task Force review reporting around 93 out of 100 cases caught and roughly 98 out of 100 non-cases correctly cleared.

Older blood tests for anti-gliadin antibodies that targeted the natural form of gliadin (the parent of the stool version of this test) have largely been retired from clinical practice. They were considered too unspecific, and reviews now describe their accuracy as inferior to newer serum assays that target deamidated gliadin peptides (DGP), tTG, and endomysium (EMA, an antibody that targets tissue transglutaminase within the connective tissue surrounding smooth muscle cells).

Gluten Reactivity Beyond Celiac Disease

Anti-gliadin antibodies are not unique to celiac disease. They have been reported at higher rates in some people with non-celiac wheat sensitivity, irritable bowel syndrome, autism with gastrointestinal symptoms, and schizophrenia, often in the absence of celiac-specific markers like tTG or EMA. Most of those reports, including the schizophrenia and autism findings and a trial of people with irritable bowel syndrome whose symptoms improved on a gluten-free diet, measured anti-gliadin IgG in blood rather than anti-gliadin IgA in stool. The signals are biologically related but not interchangeable with this test.

None of this means a positive stool anti-gliadin IgA result identifies a specific disease. It is better understood as a sign that the gut immune system is engaging with gluten in some way. Whether that matters for your symptoms is a question that has to be answered alongside other testing and a clinician's evaluation. Reviews of non-celiac gluten sensitivity have concluded that no specific biomarker for the condition has been established.

Mucosal Recovery and Persistent Reactivity

In adults already diagnosed with celiac disease, persistently high anti-gliadin antibody levels at diagnosis have been linked to incomplete gut healing on a gluten-free diet. One adult cohort identified a higher anti-gliadin antibody level at diagnosis as an independent risk factor for lack of mucosal improvement after at least 12 months on the diet. A separate expert review similarly noted that high endomysial antibody levels at diagnosis predict incomplete recovery. This evidence comes from serum-based antibody testing, not stool antibody testing, so it suggests a related signal rather than directly validating the stool assay.

Tracking Your Trend

Because stool anti-gliadin IgA has no standardized clinical cutpoints and no consensus on what counts as a meaningful change, a single reading should not drive any decision. The value, if any, comes from watching how your number behaves alongside symptoms, dietary changes, and validated celiac labs. If you make a deliberate change, like a strict gluten-free trial, retesting in 3 to 6 months can show whether your level is moving in the expected direction. After that, annual retesting is a reasonable cadence for people actively monitoring gut immune reactivity. This is expert-opinion guidance, not a formal society recommendation, since no guideline addresses stool anti-gliadin IgA retesting.

Keep in mind that fecal gluten immunogenic peptides (GIP), a different stool test, measure gluten itself in the bowel rather than your antibody response. Studies have found that nearly 9 out of 10 people on a gluten-free diet had at least one stool or urine sample positive for gluten peptides over several weeks of frequent sampling, and most of those people had negative serum tTG-IgA at the same time. If your goal is to confirm whether you are actually avoiding gluten, GIP testing answers that question more directly than antibody testing of any kind.

When Results Can Be Misleading

• Low or no gluten intake: if you have been eating little or no gluten in the weeks before the test, your gut immune system may not be producing detectable anti-gliadin IgA, even if you are genuinely sensitive to gluten when exposed. NASPGHAN suggests at least 10 grams of gluten per day (about two slices of wheat bread) for at least 8 weeks before antibody testing, and the AGA suggests three slices of wheat bread daily for 1 to 3 months.
• IgA deficiency: some people produce very little IgA at all, which can give a falsely low result. Standard celiac evaluation includes measuring total IgA in the blood for this reason.
• Antibody breakdown in the gut: stool antibodies pass through a long, enzyme-rich bowel before collection. Researchers studying these assays have flagged digestion during transit as a likely reason stool antibody levels do not correlate with blood levels.
• Non-celiac immune activity: higher anti-gliadin antibody levels (most often anti-gliadin IgG in blood, not stool IgA) have been reported in conditions like irritable bowel syndrome, autism with gut symptoms, schizophrenia, and recurrent mouth ulcers. A positive result alone does not point to a specific disease.

What to Do With an Unexpected Result

Because this is not a stand-alone diagnostic test, the most useful next step after an unexpected result is to look at the standard celiac workup. That typically means serum total IgA and serum tTG-IgA as the first-line tests, with serum EMA-IgA as a highly specific confirmatory marker when tTG-IgA is very high. In children under 2 or anyone with IgA deficiency, adding serum DGP-IgG can pick up early cases that tTG-IgA alone might miss. In one large diagnostic cohort, about 10% of biopsy-confirmed celiac cases who were negative for tTG-IgA were positive for DGP antibodies.

If standard serology comes back negative but your symptoms continue, fecal gluten immunogenic peptide testing can show whether you are still being exposed to gluten unintentionally. Persistent symptoms with negative serology and ongoing gluten exposure on GIP testing point toward dietary investigation; persistent symptoms with no gluten exposure point toward a non-gluten cause. A gastroenterologist is the right specialist to coordinate this workup, particularly if biopsy is being considered.

For preventive screening in adults who feel well, the available evidence does not support stool anti-gliadin IgA as a useful test. A large screening study of healthy adult blood donors and children found that isolated anti-gliadin antibody positivity almost never translated into a confirmed celiac diagnosis on follow-up. If you want to screen yourself for celiac disease, a serum tTG-IgA with total IgA is the better starting point.